Elite Pharma Files ANDA for Generic Anticoagulant Targeting $26B Market
ELTP is trading near its 52-week low of $0.328 (4.8% above the low).
Summary
Elite Pharmaceuticals announced the filing of an ANDA for a generic anticoagulant, targeting a $26 billion market with no current generic competition, representing a key step in its product pipeline.
Key Events · Product Development and Regulatory · ELTP
-
ANDA Filed for Generic Anticoagulant
Elite Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of an undisclosed anticoagulant drug product.
-
Targets $26 Billion Market
The branded product has reported sales of $26 billion for the twelve months ending March 2026, with no generic competition currently on the market.
-
Faces Patent Challenges
The branded product has unexpired patents and exclusivity, which Elite must address for FDA approval and commercialization.
-
Strategic Pipeline Expansion
This filing represents a significant step in expanding Elite's product pipeline into a potentially highly lucrative market, following a recent successful generic launch.
Analysis · ELTP · Life Sciences
Elite Pharmaceuticals has filed an Abbreviated New Drug Application (ANDA) for a generic anticoagulant. This is an important strategic move as the branded product has $26 billion in annual sales and currently has no generic competition. While the specific drug is undisclosed and faces unexpired patents and exclusivity, this filing positions Elite to potentially enter a highly lucrative market. This development follows the company's recent successful launch of generic methadone tablets, indicating ongoing pipeline progress.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELTP was trading at $0.34 on OTC in the Life Sciences sector, with a market capitalization of approximately $370.5M. The 52-week trading range was $0.33 to $0.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.